Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

545
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
545
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

994
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
994
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

586
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
586
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

743
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
743
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

183
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
183

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pathophysiology of Ketoacidosis: Core Curriculum 2026.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2026
Same author

The Sexual Dimorphism in Kidney Potassium Handling: A Conceptual Review.

Clinical journal of the American Society of Nephrology : CJASN·2026
Same author

Real-World Insights on Attitudes and Treatment of Hyperkalemia.

Mayo Clinic proceedings·2026
Same author

Sodium reduction and salt substitutes: impact on blood pressure and recurrent stroke.

Current opinion in cardiology·2026
Same author

Systemic effects of metabolic acidosis.

Clinical nephrology·2026
Same author

ASN Kidney Health Guidance on Potassium and Phosphorus Food Additives.

Journal of the American Society of Nephrology : JASN·2025
Same journal

Evidence-Based Medicine versus Personalized Medicine when attempting to block complement in IgA nephropathy.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2026
Same journal

Impact of immunosuppressive therapy on renal and patient survival in rapidly progressive secondary IgA nephropathy.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2026
Same journal

Severe Pregnancy-Associated Acute Kidney Injury and Maternal Vulnerability.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2026
Same journal

Correction to: Hyponatraemia-treatment standard 2024.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2026
Same journal

Effect of Semaglutide on Measured vs Estimated Glomerular Filtration Rate.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2026
Same journal

Beyond Diffusion and Convection: Is Adsorption the Third Dimension of Dialysis?

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2026
See all related articles

Related Experiment Video

Updated: Jul 1, 2025

Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique
08:11

Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique

Published on: November 11, 2022

2.8K

Hyperkalemia treatment standard.

Biff F Palmer1, Deborah J Clegg2

  • 1Professor of Internal Medicine, Department of Medicine, Division of Nephrology, University of Texas Southwestern Medical Center, Dallas, TX, USA.

Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association
|March 1, 2024
PubMed
Summary
This summary is machine-generated.

Hyperkalemia, or high potassium levels, requires prompt management. Treatment strategies vary for acute and chronic cases, focusing on immediate stabilization, shifting potassium into cells, and reducing overall body potassium.

Keywords:
SGLT2 inhibitorsacute and chronic hyperkalemiadietary potassium restrictionpatiromerrenin–angiotensin–aldosterone system (RAAS) inhibitorszirconium cyclosilicate

More Related Videos

Isolation and Kv Channel Recordings in Murine Atrial and Ventricular Cardiomyocytes
11:33

Isolation and Kv Channel Recordings in Murine Atrial and Ventricular Cardiomyocytes

Published on: March 12, 2013

13.4K
Preparation of Human Myocardial Tissue for Long-Term Cultivation
10:58

Preparation of Human Myocardial Tissue for Long-Term Cultivation

Published on: June 2, 2022

4.6K

Related Experiment Videos

Last Updated: Jul 1, 2025

Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique
08:11

Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique

Published on: November 11, 2022

2.8K
Isolation and Kv Channel Recordings in Murine Atrial and Ventricular Cardiomyocytes
11:33

Isolation and Kv Channel Recordings in Murine Atrial and Ventricular Cardiomyocytes

Published on: March 12, 2013

13.4K
Preparation of Human Myocardial Tissue for Long-Term Cultivation
10:58

Preparation of Human Myocardial Tissue for Long-Term Cultivation

Published on: June 2, 2022

4.6K

Area of Science:

  • Nephrology
  • Internal Medicine
  • Cardiology

Background:

  • Hyperkalemia is a frequent electrolyte imbalance in clinical practice.
  • Severity and risks depend on the cause and speed of potassium increase.
  • Acute hyperkalemia poses life-threatening risks, necessitating immediate intervention.

Purpose of the Study:

  • To outline management strategies for acute and chronic hyperkalemia.
  • To discuss the role of medications and dietary interventions.
  • To emphasize the importance of renin-angiotensin-aldosterone inhibitors in specific patient populations.

Main Methods:

  • Initial treatment focuses on cardiac membrane stabilization.
  • Subsequent steps involve shifting potassium into cells.
  • Long-term management includes addressing underlying causes and optimizing therapies.

Main Results:

  • Chronic hyperkalemia, though less severe acutely, is linked to increased morbidity and mortality.
  • Dietary potassium restriction is being re-evaluated, favoring a focus on non-plant sources.
  • Discontinuation of renin-angiotensin-aldosterone inhibitors is discouraged due to their proven benefits.

Conclusions:

  • Management of hyperkalemia requires a tailored approach based on acuity and patient factors.
  • Conservative measures, potassium binders, and SGLT2 inhibitors aid in managing chronic hyperkalemia.
  • Preserving beneficial therapies like RAAS inhibitors is crucial for patient outcomes.